<?xml version="1.0" encoding="UTF-8"?><measure><measureDetails><uuid>40280381-4be2-53b3-014b-e5e7f0db01ce</uuid><title>Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients</title><shortTitle>Prostate_Cancer</shortTitle><emeasureid>129</emeasureid><guid>1635c14d-e612-4fa6-96cd-285361aa7f7b</guid><version>5.0.000</version><nqfid extension="0389" root="2.16.840.1.113883.3.560.1"/><period calenderYear="true" uuid="40280381-3d61-56a7-013e-6696af854789"><startDate>00000101</startDate><stopDate>00001231</stopDate></period><steward id="2.16.840.1.113883.3.526">American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)</steward><developers><developer id="2.16.840.1.113883.3.526">American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)</developer></developers><endorsement id="2.16.840.1.113883.3.560">National Quality Forum</endorsement><description>Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer</description><copyright>Copyright 2014 American Medical Association. All Rights Reserved.</copyright><disclaimer>Physician Performance Measures (Measures) and related data specifications have been developed by the American Medical Association (AMA) - convened Physician Consortium for Performance Improvement(R) (PCPI[R]). These Measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the AMA, (on behalf of the PCPI). Neither the AMA, PCPI nor its members shall be responsible for any use of the Measures. &#xD;
&#xD;
THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. &#xD;
&#xD;
Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT[R]) or other coding contained in the specifications. &#xD;
&#xD;
CPT(R) contained in the Measure specifications is copyright 2004-2014 American Medical Association. LOINC(R) copyright 2004-2014 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2014 International Health Terminology Standards Development Organisation. ICD-10 copyright 2014 World Health Organization. All Rights Reserved.&#xD;
&#xD;
Due to technical limitations, registered trademarks are indicated by (R) or [R].</disclaimer><scoring id="PROPOR">Proportion</scoring><types><type id="PROCESS">Process</type></types><componentMeasures/><itemCount/><stratification>None</stratification><riskAdjustment>None</riskAdjustment><aggregation>None</aggregation><rationale>A bone scan is generally not required for staging prostate cancer in men with a low risk of recurrence and receiving primary therapy. This measure is written as a negative measure so that the performance goal is 100%, consistent with the other measures for this condition.</rationale><recommendations>Routine use of a bone scan is not required for staging asymptomatic men with clinically localized prostate cancer when their PSA level is equal to or less than 20.0 ng/mL. (AUA, 2013)&#xD;
&#xD;
For symptomatic patients and/or those with a life expectancy of greater than 5 years, a bone scan is appropriate for patients with any of the following: 1) T1 disease with PSA over 20 ng/mL or T2 disease with PSA over 10 ng/mL; 2) a Gleason score of 8 or higher; 3) T3 to T4 tumors; or 4) symptomatic disease. (NCCN, 2015) (Category 2A)</recommendations><improvementNotations>Higher score indicates better quality</improvementNotations><references><reference>American Urological Association (AUA). Guideline for the Management of Clinically Localized Prostate Cancer: 2007 update. J Urol. 2007;177:2106-2131.</reference><reference>American Urological Association Education and Research, Inc. PSA testing for the pretreatment staging and posttreatment management of prostate cancer: 2013 Revision of 2009 Best Practice Statement. Linthicum, MD: American Urological Association Education and Research, Inc. 2013. Available at: https://www.auanet.org/common/pdf/education/clinical-guidance/Prostate-Specific-Antigen.pdf</reference><reference>National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 4.2011. Available at www.nccn.org</reference><reference>National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1.2015. Available at www.nccn.org</reference></references><definitions>Risk Strata Definitions: Low, Intermediate, or High -&#xD;
Low Risk - PSA &lt;= 10 ng/mL; AND Gleason score 6 or less; AND clinical stage T1c or T2a. (AUA, 2007)&#xD;
Intermediate Risk - PSA &gt; 10 to 20 ng/mL; OR Gleason score 7; OR clinical stage T2b, and not qualifying for high risk. (AUA, 2007)&#xD;
High Risk - PSA &gt; 20 ng/mL; OR Gleason score 8 to 10; OR clinically localized stage T3a. (NCCN, 2011)&#xD;
&#xD;
External beam radiotherapy - external beam radiotherapy refers to 3D conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT), stereotactic body radiotherapy (SBRT), and proton beam therapy.</definitions><guidance>A higher score indicates appropriate treatment of patients with prostate cancer at low risk of recurrence.&#xD;
Only patients with prostate cancer with low risk of recurrence will be counted in the performance denominator of this measure.</guidance><transmissionFormat>TBD</transmissionFormat><initialPopDescription>All patients, regardless of age, with a diagnosis of prostate cancer</initialPopDescription><denominatorDescription>Equals Initial Population at low risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy</denominatorDescription><denominatorExclusionsDescription>None</denominatorExclusionsDescription><numeratorDescription>Patients who did not have a bone scan performed at any time since diagnosis of prostate cancer</numeratorDescription><numeratorExclusionsDescription>Not Applicable</numeratorExclusionsDescription><denominatorExceptionsDescription>Documentation of reason(s) for performing a bone scan (including documented pain, salvage therapy, other medical reasons, bone scan ordered by someone other than reporting physician)</denominatorExceptionsDescription><measurePopulationDescription>Not Applicable</measurePopulationDescription><measurePopulationExclusionsDescription>Not Applicable</measurePopulationExclusionsDescription><measureObservationsDescription>Not Applicable</measureObservationsDescription><supplementalData>For every patient evaluated by this measure also identify payer, race, ethnicity and sex.</supplementalData><qualityMeasureSet uuid="80f53cc9-4b12-4cf5-bb58-641b78ee77a7">None</qualityMeasureSet>
<finalizedDate value="201503300922-0500"/>
</measureDetails><supplementalDataElements><elementRef id="40280381-3d61-56a7-013e-6696af844783" name="ONC Administrative Sex"/><elementRef id="40280381-3d61-56a7-013e-6696af844784" name="Race"/><elementRef id="40280381-3d61-56a7-013e-6696af844785" name="Ethnicity"/><elementRef id="40280381-3d61-56a7-013e-6696af844786" name="Payer"/></supplementalDataElements><riskAdjustmentVariables/><subTreeLookUp><subTree displayName="IPP DX Overlaps" qdmVariable="false" uuid="C9A36145-7F22-47C3-9F93-8EECFD2C5AE3"><relationalOp displayName="Overlaps" type="Overlap"><elementRef displayName="Occurrence A of Prostate Cancer : Diagnosis, Active" id="40280381-3d61-56a7-013e-6696af844787" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6696af854789" type="qdm"/></relationalOp></subTree><subTree displayName="IPP Patient is Male" qdmVariable="false" uuid="152025C0-8CE5-4262-928A-7A4C8FFFD4AD"><elementRef displayName="Male : Patient Characteristic Sex" id="40280381-3d61-56a7-013e-6696af854788" type="qdm"/></subTree><subTree displayName="FirstProstateCancerTreatment" qdmVariable="true" uuid="F85DC7F4-E421-4E2D-B3B9-BBCB0444C2C8"><functionalOp displayName="FIRST" type="FIRST"><relationalOp displayName="During" type="DURING"><elementRef displayName="Prostate Cancer Treatment : Procedure, Performed" id="40280381-3d61-56a7-013e-6696af85478a" type="qdm"/><elementRef displayName="Measurement Period : Timing Element" id="40280381-3d61-56a7-013e-6696af854789" type="qdm"/></relationalOp></functionalOp></subTree><subTree displayName="Lab Test PSA SA MR sbso var and result ltet 10 " qdmVariable="false" uuid="CBB91709-3CB5-4785-8431-913729B7FDEA"><functionalOp displayName="SATISFIES ALL" type="SATISFIES ALL"><elementRef displayName="Prostate Specific Antigen Test : Laboratory Test, Performed" id="7f7ec884-6084-4c6b-96aa-715347f92622" type="qdm"/><relationalOp displayName="Starts Before Start Of" type="SBS"><functionalOp displayName="MOST RECENT" type="MOST RECENT"><elementRef displayName="Prostate Specific Antigen Test : Laboratory Test, Performed" id="7f7ec884-6084-4c6b-96aa-715347f92622" type="qdm"/></functionalOp><subTreeRef displayName="MostRecentPrCaClinicalStaging" id="F79B97CF-EFA5-4A45-8BCD-61FD9CAE0DC5" type="subTree"/></relationalOp><elementRef displayName="Prostate Specific Antigen Test : Laboratory Test, Performed" id="7f7ec884-6084-4c6b-96aa-715347f92622" type="qdm"><attribute attrUUID="f25a1853-2afc-42f9-a373-8ec907d6a832" comparisonValue="10" mode="Less Than Or Equal To" name="result" unit="ng/mL"/></elementRef></functionalOp></subTree><subTree displayName="Lab Test Gleason SA MR sbso var and result ltet 6" qdmVariable="false" uuid="84E8E544-9997-42FE-AFD2-5511E37B206D"><functionalOp displayName="SATISFIES ALL" type="SATISFIES ALL"><elementRef displayName="Gleason Score : Laboratory Test, Performed" id="40280381-3d61-56a7-013e-6696af85478f" type="qdm"/><relationalOp displayName="Starts Before Start Of" type="SBS"><functionalOp displayName="MOST RECENT" type="MOST RECENT"><elementRef displayName="Gleason Score : Laboratory Test, Performed" id="40280381-3d61-56a7-013e-6696af85478f" type="qdm"/></functionalOp><subTreeRef displayName="FirstProstateCancerTreatment" id="F85DC7F4-E421-4E2D-B3B9-BBCB0444C2C8" type="subTree"/></relationalOp><elementRef displayName="Gleason Score : Laboratory Test, Performed" id="40280381-3d61-56a7-013e-6696af85478f" type="qdm"><attribute attrUUID="4addc942-c9fc-4e33-b2e5-827b1f4692b7" comparisonValue="6" mode="Less Than Or Equal To" name="result"/></elementRef></functionalOp></subTree><subTree displayName="N Negation Bone scan saso OccA dx Prostate CA" qdmVariable="false" uuid="5D9BA5C5-D9C4-483C-A8B8-A07C56859ABA"><relationalOp displayName="Starts After Start Of" type="SAS"><elementRef displayName="Bone Scan : Diagnostic Study, Performed" id="40280381-3d61-56a7-013e-6696af854790" type="qdm"/><elementRef displayName="Occurrence A of Prostate Cancer : Diagnosis, Active" id="40280381-3d61-56a7-013e-6696af844787" type="qdm"/></relationalOp></subTree><subTree displayName="DEP Union DX Proc saso OccA dx Prostate CA" qdmVariable="false" uuid="614451E3-6AE4-4C08-B3A6-D1C9E1D5261A"><relationalOp displayName="Starts After Start Of" type="SAS"><setOp displayName="UNION" type="union"><elementRef displayName="Pain Related to Prostate Cancer : Diagnosis, Active" id="40280381-3d61-56a7-013e-6696af854791" type="qdm"/><elementRef displayName="Salvage Therapy : Procedure, Performed" id="40280381-3d61-56a7-013e-6696af854792" type="qdm"/><elementRef displayName="Bone Scan : Diagnostic Study, Performed" id="40280381-3d61-56a7-013e-6696af854790" type="qdm"><attribute attrUUID="4279ecc8-c362-4851-b5e7-2bd1d43551c7" mode="Value Set" name="reason" qdmUUID="40280381-3d61-56a7-013e-6696af854795"/></elementRef></setOp><elementRef displayName="Occurrence A of Prostate Cancer : Diagnosis, Active" id="40280381-3d61-56a7-013e-6696af844787" type="qdm"/></relationalOp></subTree><subTree displayName="MostRecentPrCaClinicalStaging" qdmVariable="true" uuid="F79B97CF-EFA5-4A45-8BCD-61FD9CAE0DC5"><functionalOp displayName="SATISFIES ALL" type="SATISFIES ALL"><elementRef displayName="Clinical Staging Procedure : Procedure, Performed" id="40280381-3d61-56a7-013e-6696af85478d" type="qdm"/><functionalOp displayName="MOST RECENT" type="MOST RECENT"><relationalOp displayName="Starts Before Start Of" type="SBS"><elementRef displayName="Clinical Staging Procedure : Procedure, Performed" id="40280381-3d61-56a7-013e-6696af85478d" type="qdm"/><subTreeRef displayName="FirstProstateCancerTreatment" id="F85DC7F4-E421-4E2D-B3B9-BBCB0444C2C8" type="subTree"/></relationalOp></functionalOp><functionalOp displayName="SATISFIES ANY" type="SATISFIES ANY"><elementRef displayName="Clinical Staging Procedure : Procedure, Performed" id="40280381-3d61-56a7-013e-6696af85478d" type="qdm"/><elementRef displayName="Clinical Staging Procedure : Procedure, Performed" id="40280381-3d61-56a7-013e-6696af85478d" type="qdm"><attribute attrUUID="bd2c0ff0-28aa-49e8-97a0-a18be36016c3" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6696af85478b"/></elementRef><elementRef displayName="Clinical Staging Procedure : Procedure, Performed" id="40280381-3d61-56a7-013e-6696af85478d" type="qdm"><attribute attrUUID="216a9160-3227-4871-a34d-2be9c2fd7821" mode="Value Set" name="result" qdmUUID="40280381-3d61-56a7-013e-6696af85478c"/></elementRef></functionalOp></functionalOp></subTree></subTreeLookUp><measureGrouping><group sequence="1"><clause displayName="Initial Population 1" type="initialPopulation" uuid="1F136C5C-E0FE-4370-B872-1631F1F359D1"><logicalOp displayName="AND" type="and"><subTreeRef displayName="IPP DX Overlaps" id="C9A36145-7F22-47C3-9F93-8EECFD2C5AE3" type="subTree"/><subTreeRef displayName="IPP Patient is Male" id="152025C0-8CE5-4262-928A-7A4C8FFFD4AD" type="subTree"><comment displayName="comment" type="comment"/></subTreeRef></logicalOp></clause><clause displayName="Denominator 1" type="denominator" uuid="EA79130D-4538-4087-A213-921E32D8A59D"><logicalOp displayName="AND" type="and"><comment displayName="comment" type="comment"/><subTreeRef displayName="FirstProstateCancerTreatment" id="F85DC7F4-E421-4E2D-B3B9-BBCB0444C2C8" type="subTree"/><subTreeRef displayName="Lab Test PSA SA MR sbso var and result ltet 10 " id="CBB91709-3CB5-4785-8431-913729B7FDEA" type="subTree"><comment displayName="comment" type="comment"/></subTreeRef><subTreeRef displayName="Lab Test Gleason SA MR sbso var and result ltet 6" id="84E8E544-9997-42FE-AFD2-5511E37B206D" type="subTree"><comment displayName="comment" type="comment"/></subTreeRef></logicalOp></clause><clause displayName="Denominator Exceptions 1" type="denominatorExceptions" uuid="DC2D0B45-57CC-4C34-9F7C-556354EF0225"><logicalOp displayName="OR" type="or"><comment displayName="comment" type="comment"/><subTreeRef displayName="DEP Union DX Proc saso OccA dx Prostate CA" id="614451E3-6AE4-4C08-B3A6-D1C9E1D5261A" type="subTree"/></logicalOp></clause><clause displayName="Numerator 1" type="numerator" uuid="DC91E60A-F924-4549-8B63-F2EE63782236"><logicalOp displayName="AND" type="and"><comment displayName="comment" type="comment"/><logicalOp displayName="AND NOT" type="andNot"><comment displayName="comment" type="comment"/><subTreeRef displayName="N Negation Bone scan saso OccA dx Prostate CA" id="5D9BA5C5-D9C4-483C-A8B8-A07C56859ABA" type="subTree"/></logicalOp></logicalOp></clause><clause displayName="denominatorExclusions" type="denominatorExclusions" uuid="68fe9c21-0bb3-4249-941a-8f140266d5f2"><logicalOp displayName="AND" type="and"/></clause><clause displayName="numeratorExclusions" type="numeratorExclusions" uuid="146fa889-e393-478f-8bc1-e98ac154ca72"><logicalOp displayName="AND" type="and"/></clause><clause displayName="stratum" type="stratum" uuid="bfb512f2-254a-4cb4-93dd-f179ef09c8bb"/></group></measureGrouping><elementLookUp><qdm datatype="Patient Characteristic Birthdate" id="99067940-d644-48d2-a687-85c274e6c81f" name="Birthdate" oid="21112-8" suppDataElement="false" taxonomy="SNOMED-CT" uuid="99067940-d644-48d2-a687-85c274e6c81f" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Diagnostic Study, Performed" id="40280381-3d61-56a7-013e-6696af854790" name="Bone Scan" oid="2.16.840.1.113883.3.526.3.320" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6696af854790" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Performed" id="40280381-3d61-56a7-013e-6696af85478d" name="Clinical Staging Procedure" oid="2.16.840.1.113883.3.526.3.1098" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6696af85478d" version="1.0"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Ethnicity" id="40280381-3d61-56a7-013e-6696af844785" name="Ethnicity" oid="2.16.840.1.114222.4.11.837" suppDataElement="true" taxonomy="CDCREC" uuid="40280381-3d61-56a7-013e-6696af844785" version="1"/><qdm datatype="Patient Characteristic Expired" id="76fcc22d-fff4-4dd3-a48d-daa821084f6a" name="Expired" oid="419099009" suppDataElement="false" taxonomy="SNOMED-CT" uuid="76fcc22d-fff4-4dd3-a48d-daa821084f6a" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Laboratory Test, Performed" id="40280381-3d61-56a7-013e-6696af85478f" name="Gleason Score" oid="2.16.840.1.113883.3.526.3.397" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6696af85478f" version="1.0"/><qdm codeSystemName="National Quality Forum" datatype="Patient Characteristic Sex" id="40280381-3d61-56a7-013e-6696af854788" name="Male" oid="2.16.840.1.113883.3.560.100.1" suppDataElement="false" taxonomy="AdministrativeSex" uuid="40280381-3d61-56a7-013e-6696af854788" version="1"/><qdm codeSystemName="National Quality Forum" datatype="Timing Element" id="40280381-3d61-56a7-013e-6696af854789" name="Measurement Period" oid="2.16.840.1.113883.3.67.1.101.1.53" suppDataElement="false" taxonomy="NQF" uuid="40280381-3d61-56a7-013e-6696af854789" version="1"/><qdm codeSystemName="National Library of Medicine" datatype="Patient Characteristic Sex" id="40280381-3d61-56a7-013e-6696af844783" name="ONC Administrative Sex" oid="2.16.840.1.113762.1.4.1" suppDataElement="true" taxonomy="AdministrativeGender" uuid="40280381-3d61-56a7-013e-6696af844783" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Diagnosis, Active" id="40280381-3d61-56a7-013e-6696af854791" name="Pain Related to Prostate Cancer" oid="2.16.840.1.113883.3.526.3.451" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6696af854791" version="1"/><qdm codeSystemName="PHDSC" datatype="Patient Characteristic Payer" id="40280381-3d61-56a7-013e-6696af844786" name="Payer" oid="2.16.840.1.114222.4.11.3591" suppDataElement="true" taxonomy="SOP" uuid="40280381-3d61-56a7-013e-6696af844786" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Diagnosis, Active" id="40280381-3d61-56a7-013e-6696af844787" instance="Occurrence A" name="Prostate Cancer" oid="2.16.840.1.113883.3.526.3.319" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6696af844787" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6696af85478b" name="Prostate Cancer Primary Tumor Size T1c" oid="2.16.840.1.113883.3.526.3.1325" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6696af85478b" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6696af85478c" name="Prostate Cancer Primary Tumor Size T2a" oid="2.16.840.1.113883.3.526.3.1326" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6696af85478c" version="1.0"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Performed" id="40280381-3d61-56a7-013e-6696af85478a" name="Prostate Cancer Treatment" oid="2.16.840.1.113883.3.526.3.398" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6696af85478a" version="1.0"/><qdm datatype="Laboratory Test, Performed" id="7f7ec884-6084-4c6b-96aa-715347f92622" name="Prostate Specific Antigen Test" oid="2.16.840.1.113883.3.526.3.401" suppDataElement="false" taxonomy="Grouping" uuid="7f7ec884-6084-4c6b-96aa-715347f92622" version="1.0"/><qdm codeSystemName="CDC NCHS" datatype="Patient Characteristic Race" id="40280381-3d61-56a7-013e-6696af844784" name="Race" oid="2.16.840.1.114222.4.11.836" suppDataElement="true" taxonomy="CDCREC" uuid="40280381-3d61-56a7-013e-6696af844784" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="attribute" id="40280381-3d61-56a7-013e-6696af854795" name="Reason Documented" oid="2.16.840.1.113883.3.526.3.1494" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6696af854795" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Procedure, Performed" id="40280381-3d61-56a7-013e-6696af854792" name="Salvage Therapy" oid="2.16.840.1.113883.3.526.3.399" suppDataElement="false" taxonomy="Grouping" uuid="40280381-3d61-56a7-013e-6696af854792" version="1"/><qdm codeSystemName="American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)" datatype="Diagnosis, Active" id="5873edbf-df4c-4002-8366-c3387a61eebe" name="Prostate Cancer" oid="2.16.840.1.113883.3.526.3.319" suppDataElement="false" taxonomy="Grouping" uuid="5873edbf-df4c-4002-8366-c3387a61eebe" version="1"/></elementLookUp></measure>